Simone Fulda

List of Publications by Year
in descending order

263 papers	33,883 citations	15880 67 h-index	4853 174 g-index
293 all docs	293 docs citations	293 times ranked	51515 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
2	Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell, 2017, 171, 273-285.	13.5	4,081
3	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541.	5.0	4,036
4	Targeting mitochondria for cancer therapy. Nature Reviews Drug Discovery, 2010, 9, 447-464.	21.5	1,389
5	Molecular definitions of autophagy and related processes. EMBO Journal, 2017, 36, 1811-1836.	3.5	1,230
6	The landscape of genomic alterations across childhood cancers. Nature, 2018, 555, 321-327.	13.7	1,068
7	Cellular Stress Responses: Cell Survival and Cell Death. International Journal of Cell Biology, 2010, 2010, 1-23.	1.0	984
8	Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nature Medicine, 2002, 8, 808-815.	15.2	741
9	Targeting IAP proteins for therapeutic intervention in cancer. Nature Reviews Drug Discovery, 2012, 11, 109-124.	21.5	712
10	Endoplasmic reticulum stress signalling â€" from basic mechanisms to clinical applications. FEBS Journal, 2019, 286, 241-278.	2.2	568
11	Tumor resistance to apoptosis. International Journal of Cancer, 2009, 124, 511-515.	2.3	510
12	Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene, 2001, 20, 5865-5877.	2.6	410
13	Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. Journal of Clinical Investigation, 2018, 128, 3341-3355.	3.9	406
14	Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene, 2002, 21, 2283-2294.	2.6	358
15	Activation of Mitochondria and Release of Mitochondrial Apoptogenic Factors by Betulinic Acid. Journal of Biological Chemistry, 1998, 273, 33942-33948.	1.6	323
16	Betulinic Acid for Cancer Treatment and Prevention. International Journal of Molecular Sciences, 2008, 9, 1096-1107.	1.8	267
17	TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-Î°B. Oncogene, 2003, 22, 3842-3852.	2.6	262
18	Next-generation personalised medicine for high-risk paediatric cancer patients â€" The INFORM pilot study. European Journal of Cancer, 2016, 65, 91-101.	1.3	262

#	Article	IF	Citations
19	Sensitization for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by the Chemopreventive Agent Resveratrol. Cancer Research, 2004, 64, 337-346.	0.4	250
20	IFNÎ³ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene, 2002, 21, 2295-2308.	2.6	247
21	Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. Nature Communications, 2015, 6, 8940.	5.8	242
22	Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene, 2001, 20, 1063-1075.	2.6	220
23	Activation of Akt Predicts Poor Outcome in Neuroblastoma. Cancer Research, 2007, 67, 735-745.	0.4	218
24	Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discovery Today, 2010, 15, 757-765.	3.2	213
25	Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene, 2004, 23, 6702-6711.	2.6	193
26	Targeting mitochondrial apoptosis by betulinic acid in human cancers. Drug Discovery Today, 2009, 14, 885-890.	3.2	181
27	Targeting apoptosis for anticancer therapy. Seminars in Cancer Biology, 2015, 31, 84-88.	4.3	174
28	Betulinic acid: A new cytotoxic agent against malignant brain-tumor cells. , 1999, 82, 435-441.		171
29	Modulation of Apoptosis by Natural Products for Cancer Therapy. Planta Medica, 2010, 76, 1075-1079.	0.7	171
30	Caspase-8 in cancer biology and therapy. Cancer Letters, 2009, 281, 128-133.	3.2	162
31	Targeting Apoptosis Pathways in Cancer Therapy. Current Cancer Drug Targets, 2004, 4, 569-576.	0.8	158
32	Promises and Challenges of Smac Mimetics as Cancer Therapeutics. Clinical Cancer Research, 2015, 21, 5030-5036.	3.2	152
33	Linear ubiquitination of cytosolic Salmonella Typhimurium activates NF-Î°B and restricts bacterial proliferation. Nature Microbiology, 2017, 2, 17066.	5.9	145
34	Targeting XIAP Bypasses Bcl-2â€"Mediated Resistance to TRAIL and Cooperates with TRAIL to Suppress Pancreatic Cancer Growth <i>In vitro</i> and <i>In vivo</i>. Cancer Research, 2008, 68, 7956-7965.	0.4	143
35	Chemosensitivity of solid tumor cellsin vitro is related to activation of the CD95 system. , 1998, 76, 105-114.		141
36	Small Molecule XIAP Inhibitors Enhance TRAIL-Induced Apoptosis and Antitumor Activity in Preclinical Models of Pancreatic Carcinoma. Cancer Research, 2009, 69, 2425-2434.	0.4	140

#	Article	IF	Citations
37	Phosphatidylinositol 3-Kinase Inhibition Broadly Sensitizes Glioblastoma Cells to Death Receptorâ€“ and Drug-Induced Apoptosis. Cancer Research, 2008, 68, 6271-6280.	0.4	137
38	Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors. Medical and Pediatric Oncology, 2000, 35, 616-618.	1.0	132
39	Resveratrol modulation of signal transduction in apoptosis and cell survival: A mini-review. Cancer Detection and Prevention, 2006, 30, 217-223.	2.1	132
40	Evasion of Apoptosis as a Cellular Stress Response in Cancer. International Journal of Cell Biology, 2010, 2010, 1-6.	1.0	131
41	Betulinic acid: A natural product with anticancer activity. Molecular Nutrition and Food Research, 2009, 53, 140-146.	1.5	129
42	Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2â€“mediated resistance. Blood, 2009, 113, 1710-1722.	0.6	127
43	Activation of the CD95 (APO-1/Fas) pathway in drug- and Î³-irradiation-induced apoptosis of brain tumor cells. Cell Death and Differentiation, 1998, 5, 884-893.	5.0	122
44	Lipoxygenase inhibitors protect acute lymphoblastic leukemia cells from ferroptotic cell death. Biochemical Pharmacology, 2017, 140, 41-52.	2.0	122
45	MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene, 1999, 18, 1479-1486.	2.6	118
46	Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. Blood, 2000, 95, 301-308.	0.6	115
47	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discovery, 2021, 11, 2764-2779.	7.7	110
48	The mechanism of necroptosis in normal and cancer cells. Cancer Biology and Therapy, 2013, 14, 999-1004.	1.5	102
49	Small-Molecule XIAP Inhibitors Enhance Î³-Irradiation-Induced Apoptosis in Glioblastoma. Neoplasia, 2009, 11, 743-W9.	2.3	98
50	APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Efficacy Independent of Cross-Linking via FcÎ³ Receptors. Molecular Cancer Therapeutics, 2013, 12, 2735-2747.	1.9	92
51	MycN and IFNÎ³ cooperate in apoptosis of human neuroblastoma cells. Oncogene, 1998, 17, 339-346.	2.6	91
52	Targeting of XIAP Combined with Systemic Mesenchymal Stem Cell-Mediated Delivery of sTRAIL Ligand Inhibits Metastatic Growth of Pancreatic Carcinoma Cells. Stem Cells, 2010, 28, 2109-2120.	1.4	91
53	Autophagy in Cancer Therapy. Frontiers in Oncology, 2017, 7, 128.	1.3	91
54	Sensitization for Anticancer Drug-Induced Apoptosis by Betulinic Acid. Neoplasia, 2005, 7, 162-170.	2.3	87

#	Article	IF	Citations
55	Smac Mimetic Bypasses Apoptosis Resistance in FADD- or Caspase-8-Deficient Cells by Priming for Tumor Necrosis Factor Î±-Induced Necroptosis. Neoplasia, 2011, 13, 971-IN29.	2.3	86
56	IAP antagonists: promising candidates for cancer therapy. Drug Discovery Today, 2010, 15, 210-219.	3.2	85
57	Targeting extrinsic apoptosis in cancer: Challenges and opportunities. Seminars in Cell and Developmental Biology, 2015, 39, 20-25.	2.3	84
58	HIF-1-Regulated Glucose Metabolism: A Key to Apoptosis Resistance?. Cell Cycle, 2007, 6, 790-792.	1.3	83
59	Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells. Cell Death and Differentiation, 1999, 6, 471-480.	5.0	80
60	Identification of c-FLIPL and c-FLIPS as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells. Gut, 2011, 60, 225-237.	6.1	80
61	Bortezomib Primes Glioblastoma, Including Glioblastoma Stem Cells, for TRAIL by Increasing tBid Stability and Mitochondrial Apoptosis. Clinical Cancer Research, 2011, 17, 4019-4030.	3.2	80
62	Therapeutic exploitation of necroptosis for cancer therapy. Seminars in Cell and Developmental Biology, 2014, 35, 51-56.	2.3	80
63	AT 101 induces early mitochondrial dysfunction and HMOX1 (heme oxygenase 1) to trigger mitophagic cell death in glioma cells. Autophagy, 2018, 14, 1693-1709.	4.3	79
64	Apoptosis Signaling in Tumor Therapy. Annals of the New York Academy of Sciences, 2004, 1028, 150-156.	1.8	78
65	Molecular Pathways: Targeting Inhibitor of Apoptosis Proteins in Cancerâ€"From Molecular Mechanism to Therapeutic Application. Clinical Cancer Research, 2014, 20, 289-295.	3.2	78
66	The dual PI3K/mTOR inhibitor NVPâ€BEZ235 and chloroquine synergize to trigger apoptosis <i>via</i> mitochondrialâ€lysosomal crossâ€talk. International Journal of Cancer, 2013, 132, 2682-2693.	2.3	72
67	Regulation of necroptosis signaling and cell death by reactive oxygen species. Biological Chemistry, 2016, 397, 657-660.	1.2	72
68	TRAIL-Induced Apoptosis Is Preferentially Mediated via TRAIL Receptor 1 in Pancreatic Carcinoma Cells and Profoundly Enhanced by XIAP Inhibitors. Clinical Cancer Research, 2010, 16, 5734-5749.	3.2	71
69	Oncogenic RAS Mutants Confer Resistance of RMS13 Rhabdomyosarcoma Cells to Oxidative Stress-Induced Ferroptotic Cell Death. Frontiers in Oncology, 2015, 5, 131.	1.3	71
70	Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics. Oncotarget, 2017, 8, 48794-48806.	0.8	70
71	Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury. Cell Death and Disease, 2017, 8, e2904-e2904.	2.7	69
72	Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis. Cancer Letters, 2014, 344, 101-109.	3.2	68

#	Article	IF	Citations
73	Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells. Oncogene, 2004, 23, 7611-7620.	2.6	67
74	Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors. Current Cancer Drug Targets, 2008, 8, 132-140.	0.8	67
75	Apoptosis signaling in cancer stem cells. International Journal of Biochemistry and Cell Biology, 2010, 42, 31-38.	1.2	67
76	Single-molecule imaging reveals the oligomeric state of functional TNFÎ±-induced plasma membrane TNFR1 clusters in cells. Science Signaling, 2020, 13, .	1.6	67
77	Smac mimetics as IAP antagonists. Seminars in Cell and Developmental Biology, 2015, 39, 132-138.	2.3	66
78	ATF4 links ER stress with reticulophagy in glioblastoma cells. Autophagy, 2021, 17, 2432-2448.	4.3	66
79	Sensitization for Î³-Irradiationâ€"Induced Apoptosis by Second Mitochondria-Derived Activator of Caspase. Cancer Research, 2005, 65, 10502-10513.	0.4	64
80	NF-ÎºB Is Required for Smac Mimetic-Mediated Sensitization of Glioblastoma Cells for Î³-Irradiationâ€"Induced Apoptosis. Molecular Cancer Therapeutics, 2011, 10, 1867-1875.	1.9	63
81	Modulation of mitochondrial apoptosis by PI3K inhibitors. Mitochondrion, 2013, 13, 195-198.	1.6	63
82	Apoptosis pathways and their therapeutic exploitation in pancreatic cancer. Journal of Cellular and Molecular Medicine, 2009, 13, 1221-1227.	1.6	62
83	Mitochondria as Therapeutic Targets for the Treatment of Malignant Disease. Antioxidants and Redox Signaling, 2011, 15, 2937-2949.	2.5	62
84	Biglycan is a new high-affinity ligand for CD14 in macrophages. Matrix Biology, 2019, 77, 4-22.	1.5	62
85	Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma. Cancer Letters, 2013, 337, 200-209.	3.2	60
86	Smac mimetic triggers necroptosis in pancreatic carcinoma cells when caspase activation is blocked. Cancer Letters, 2016, 380, 31-38.	3.2	60
87	Inhibitor of apoptosis proteins as targets for anticancer therapy. Expert Review of Anticancer Therapy, 2007, 7, 1255-1264.	1.1	59
88	Pan-Mammalian Target of Rapamycin (mTOR) Inhibitor AZD8055 Primes Rhabdomyosarcoma Cells for ABT-737-induced Apoptosis by Down-regulating Mcl-1 Protein. Journal of Biological Chemistry, 2013, 288, 35287-35296.	1.6	57
89	Interference with the HSF1/HSP70/BAG3 Pathway Primes Glioma Cells to Matrix Detachment and BH3 Mimeticâ€"Induced Apoptosis. Molecular Cancer Therapeutics, 2017, 16, 156-168.	1.9	57
90	Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). International Journal of Cancer, 2000, 88, 252-259.	2.3	56

#	Article	IF	Citations
91	Identification of a novel proâ€apopotic function of NFâ€ÎºB in the DNA damage response. Journal of Cellular and Molecular Medicine, 2009, 13, 4239-4256.	1.6	56
92	Targeting Aberrant PI3K/Akt Activation by PI103 Restores Sensitivity to TRAIL-Induced Apoptosis in Neuroblastoma. Clinical Cancer Research, 2011, 17, 3233-3247.	3.2	56
93	Regulation of apoptosis pathways in cancer stem cells. Cancer Letters, 2013, 338, 168-173.	3.2	56
94	A Novel Paradigm to Trigger Apoptosis in Chronic Lymphocytic Leukemia. Cancer Research, 2009, 69, 8977-8986.	0.4	55
95	Targeting ferroptosis in rhabdomyosarcoma cells. International Journal of Cancer, 2020, 146, 510-520.	2.3	55
96	Bortezomib Primes Neuroblastoma Cells for TRAIL-Induced Apoptosis by Linking the Death Receptor to the Mitochondrial Pathway. Clinical Cancer Research, 2011, 17, 3204-3218.	3.2	53
97	PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway. Molecular Cancer Therapeutics, 2015, 14, 2818-2830.	1.9	52
98	Loss of Caspase-8 Expression Does Not Correlate with MYCN Amplification, Aggressive Disease, or Prognosis in Neuroblastoma. Cancer Research, 2006, 66, 10016-10023.	0.4	51
99	Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells. Cancer Letters, 2015, 366, 32-43.	3.2	51
100	RSL3 and Erastin differentially regulate redox signaling to promote Smac mimetic-induced cell death. Oncotarget, 2016, 7, 63779-63792.	0.8	50
101	USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive Bâ€cell lymphoma. EMBO Molecular Medicine, 2016, 8, 851-862.	3.3	50
102	Therapeutic Exploitation of Apoptosis and Autophagy for Glioblastoma. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 438-449.	0.9	50
103	Loperamide, pimozide, and STF-62247 trigger autophagy-dependent cell death in glioblastoma cells. Cell Death and Disease, 2018, 9, 994.	2.7	49
104	USP22 controls necroptosis by regulating receptorâ€interacting protein kinase 3 ubiquitination. EMBO Reports, 2021, 22, e50163.	2.0	48
105	A Bak-dependent mitochondrial amplification step contributes to Smac mimetic/glucocorticoid-induced necroptosis. Cell Death and Differentiation, 2017, 24, 83-97.	5.0	47
106	Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells. Cell Death and Disease, 2017, 8, e2879-e2879.	2.7	46
107	Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma. Oncotarget, 2015, 6, 8722-8735.	0.8	46
108	Targeting redox homeostasis in rhabdomyosarcoma cells: GSH-depleting agents enhance auranofin-induced cell death. Cell Death and Disease, 2017, 8, e3067-e3067.	2.7	43

#	Article	IF	Citations
109	Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications. EMBO Molecular Medicine, 2012, 4, 545-556.	3.3	42
110	Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly. Blood, 2014, 124, 240-250.	0.6	42
111	Cell death-based treatment of glioblastoma. Cell Death and Disease, 2018, 9, 121.	2.7	42
112	Sequential Dosing in Chemosensitization: Targeting the PI3K/Akt/mTOR Pathway in Neuroblastoma. PLoS ONE, 2013, 8, e83128.	1.1	42
113	Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-XL and MCL-1 leads to rapid induction of intrinsic apoptosis. Cancer Letters, 2020, 482, 19-32.	3.2	41
114	Apoptosis pathways in neuroblastoma therapy. Cancer Letters, 2003, 197, 131-135.	3.2	40
115	Signaling through death receptors in cancer therapy. Current Opinion in Pharmacology, 2004, 4, 327-332.	1.7	40
116	Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity. Oncogene, 2005, 24, 7190-7202.	2.6	40
117	Synthetic lethality by co-targeting mitochondrial apoptosis and PI3K/Akt/mTOR signaling. Mitochondrion, 2014, 19, 85-87.	1.6	40
118	Interferons Transcriptionally Up-Regulate MLKL Expression in Cancer Cells. Neoplasia, 2019, 21, 74-81.	2.3	40
119	Redox Modulation and Induction of Ferroptosis as a New Therapeutic Strategy in Hepatocellular Carcinoma. Translational Oncology, 2020, 13, 100785.	1.7	40
120	Cell death in hematological tumors. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 409-423.	2.2	39
121	Autophagy activation, lipotoxicity and lysosomal membrane permeabilization synergize to promote pimozide- and loperamide-induced glioma cell death. Autophagy, 2021, 17, 3424-3443.	4.3	39
122	Targeting c-FLICE-like inhibitory protein (CFLAR) in cancer. Expert Opinion on Therapeutic Targets, 2013, 17, 195-201.	1.5	38
123	Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells. Cancer Letters, 2018, 428, 160-172.	3.2	38
124	Death Receptor Signaling in Cancer Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2003, 3, 253-262.	7.0	38
125	Exploiting death receptor signaling pathways for tumor therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2004, 1705, 27-41.	3.3	36
126	Regulation of tumorigenic Wnt signaling by cyclooxygenase-2, 5-lipoxygenase and their pharmacological inhibitors: A basis for novel drugs targeting cancer cells?. , 2016, 157, 43-64.		36

#	Article	IF	Citations
127	Smac mimetics and type II interferon synergistically induce necroptosis in various cancer cell lines. Cancer Letters, 2017, 410, 228-237.	3.2	36
128	Cell cycle arrest in mitosis promotes interferon-induced necroptosis. Cell Death and Differentiation, 2019, 26, 2046-2060.	5.0	36
129	Requirement of Nuclear Factor Î°B for Smac Mimeticâ€"Mediated Sensitization of Pancreatic Carcinoma Cells for Gemcitabine-Induced Apoptosis. Neoplasia, 2011, 13, 1162-IN21.	2.3	35
130	Exploiting mitochondrial apoptosis for the treatment of cancer. Mitochondrion, 2010, 10, 598-603.	1.6	34
131	Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis. Experimental Cell Research, 2012, 318, 1208-1212.	1.2	34
132	Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children. Oncotarget, 2017, 8, 66137-66153.	0.8	34
133	Targeting X-Linked Inhibitor of Apoptosis Protein to Increase the Efficacy of Endoplasmic Reticulum Stress-Induced Apoptosis for Melanoma Therapy. Journal of Investigative Dermatology, 2010, 130, 2250-2258.	0.3	33
134	Inhibitor of Apoptosis (IAP) proteins as therapeutic targets for radiosensitization of human cancers. Cancer Treatment Reviews, 2012, 38, 760-766.	3.4	33
135	Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA. Cancer Letters, 2014, 351, 50-58.	3.2	33
136	Synergistic interaction of Smac mimetic and IFNÎ± to trigger apoptosis in acute myeloid leukemia cells. Cancer Letters, 2014, 355, 224-231.	3.2	33
137	Targeting Inhibitor of Apoptosis Proteins (IAPs) for Cancer Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2008, 8, 533-539.	0.9	32
138	Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95â€induced apoptosis. International Journal of Cancer, 2010, 126, 2216-2228.	2.3	32
139	Smac mimetic and oleanolic acid synergize to induce cell death in human hepatocellular carcinoma cells. Cancer Letters, 2015, 365, 47-56.	3.2	32
140	Identification of a novel oxidative stress induced cell death by Sorafenib and oleanolic acid in human hepatocellular carcinoma cells. Biochemical Pharmacology, 2016, 118, 9-17.	2.0	32
141	Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275. Anti-Cancer Drugs, 2011, 22, 494-499.	0.7	31
142	Chloroquine overcomes resistance of lung carcinoma cells to the dual PI3K/mTOR inhibitor PI103 by lysosome-mediated apoptosis. Anti-Cancer Drugs, 2013, 24, 14-19.	0.7	31
143	Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand (TRAIL). Advances in Experimental Medicine and Biology, 2014, 818, 167-180.	0.8	31
144	Autophagy and cell death. Autophagy, 2012, 8, 1250-1251.	4.3	30

#	Article	IF	Citations
145	Structure-activity studies on N -Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation. European Journal of Medicinal Chemistry, 2018, 144, 52-67.	2.6	30
146	Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma. Haematologica, 2020, 105, 2150-2163.	1.7	30
147	Targeting Apoptosis Signaling Pathways for Anticancer Therapy. Frontiers in Oncology, 2011, 1, 23.	1.3	29
148	GDC-0941 enhances the lysosomal compartment via TFEB and primes glioblastoma cells to lysosomal membrane permeabilization and cell death. Cancer Letters, 2013, 329, 27-36.	3.2	29
149	BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis. Oncogene, 2018, 37, 5325-5339.	2.6	29
150	Modulation of TRAIL Signaling for Cancer Therapy. Vitamins and Hormones, 2004, 67, 275-290.	0.7	28
151	Smac Mimetic-Induced Upregulation of CCL2/MCP-1 Triggers Migration and Invasion of Glioblastoma Cells and Influences the Tumor Microenvironment in a Paracrine Manner. Neoplasia, 2015, 17, 481-489.	2.3	28
152	Cotreatment with Smac mimetics and demethylating agents induces both apoptotic and necroptotic cell death pathways in acute lymphoblastic leukemia cells. Cancer Letters, 2016, 375, 127-132.	3.2	28
153	Repurposing anticancer drugs for targeting necroptosis. Cell Cycle, 2018, 17, 829-832.	1.3	28
154	The SMAC mimetic BV6 sensitizes colorectal cancer cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis. Radiation Oncology, 2015, 10, 198.	1.2	27
155	Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML. Cell Death and Disease, 2019, 10, 917.	2.7	27
156	RIP1 Protein-dependent Assembly of a Cytosolic Cell Death Complex Is Required for Inhibitor of Apoptosis (IAP) Inhibitor-mediated Sensitization to Lexatumumab-induced Apoptosis*. Journal of Biological Chemistry, 2012, 287, 38767-38777.	1.6	26
157	Synergistic induction of apoptosis by a poloâ€like kinase 1 inhibitor and microtubuleâ€interfering drugs in <scp>E</scp>wing sarcoma cells. International Journal of Cancer, 2016, 138, 497-506.	2.3	26
158	Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma. Cancer Letters, 2015, 365, 37-46.	3.2	25
159	Sorafenib inhibits therapeutic induction of necroptosis in acute leukemia cells. Oncotarget, 2017, 8, 68208-68220.	0.8	25
160	MycN sensitizes neuroblastoma cells for drug-triggered apoptosis. Medical and Pediatric Oncology, 2000, 35, 582-584.	1.0	24
161	Alternative Cell Death Pathways and Cell Metabolism. International Journal of Cell Biology, 2013, 2013, 1-4.	1.0	24
162	Molecular Pathways: Targeting Death Receptors and Smac Mimetics. Clinical Cancer Research, 2014, 20, 3915-3920.	3.2	24

#	Article	IF	Citations
163	BCL-xL-selective BH3 mimetic sensitizes rhabdomyosarcoma cells to chemotherapeutics by activation of the mitochondrial pathway of apoptosis. Cancer Letters, 2018, 412, 131-142.	3.2	24
164	The novel dual BET/HDAC inhibitor TW09 mediates cell death by mitochondrial apoptosis in rhabdomyosarcoma cells. Cancer Letters, 2020, 486, 46-57.	3.2	24
165	Safety and tolerability of TRAIL receptor agonists in cancer treatment. European Journal of Clinical Pharmacology, 2015, 71, 525-527.	0.8	23
166	Sensitization of acute lymphoblastic leukemia cells for LCL161-induced cell death by targeting redox homeostasis. Biochemical Pharmacology, 2016, 105, 14-22.	2.0	23
167	The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma. Cell Death and Disease, 2021, 12, 885.	2.7	22
168	Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia. British Journal of Haematology, 2009, 145, 441-454.	1.2	21
169	Shifting the balance of mitochondrial apoptosis: therapeutic perspectives. Frontiers in Oncology, 2012, 2, 121.	1.3	21
170	Hedgehog Inhibitors in Rhabdomyosarcoma: A Comparison of Four Compounds and Responsiveness of Four Cell Lines. Frontiers in Oncology, 2015, 5, 130.	1.3	21
171	Identification of a synergistic combination of Smac mimetic and Bortezomib to trigger cell death in B-cell non-Hodgkin lymphoma cells. Cancer Letters, 2017, 405, 63-72.	3.2	21
172	Therapeutic opportunities based on caspase modulation. Seminars in Cell and Developmental Biology, 2018, 82, 150-157.	2.3	21
173	Targeting Inhibitor of Apoptosis Proteins (IAPs) for Diagnosis and Treatment of Human Diseases. Recent Patents on Anti-Cancer Drug Discovery, 2006, 1, 81-89.	0.8	20
174	Genetic deletion of Nox4 enhances cancerogen-induced formation of solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	20
175	The pleiotropic profile of the indirubin derivative 6BIO overcomes TRAIL resistance in cancer. Biochemical Pharmacology, 2014, 91, 157-167.	2.0	19
176	Targeting autophagy for the treatment of cancer. Biological Chemistry, 2018, 399, 673-677.	1.2	19
177	A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma. British Journal of Cancer, 2020, 122, 1544-1551.	2.9	19
178	Targeting Apoptosis Resistance in Rhabdomyosarcoma. Current Cancer Drug Targets, 2008, 8, 536-544.	0.8	18
179	The Smac Mimetic BV6 Improves NK Cell-Mediated Killing of Rhabdomyosarcoma Cells by Simultaneously Targeting Tumor and Effector Cells. Frontiers in Immunology, 2017, 8, 202.	2.2	18
180	Cooperative TRAIL production mediates IFNÎ±/Smac mimetic-induced cell death in TNFÎ±-resistant solid cancer cells. Oncotarget, 2016, 7, 3709-3725.	0.8	18

#	Article	IF	Citations
181	Targeting inhibitor of apoptosis proteins by <scp>S</scp>mac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia. International Journal of Cancer, 2015, 137, 2959-2970.	2.3	17
182	Arsenic trioxide induces Noxa-dependent apoptosis in rhabdomyosarcoma cells and synergizes with antimicrotubule drugs. Cancer Letters, 2016, 381, 287-295.	3.2	17
183	Congenital embryonal rhabdomyosarcoma caused by heterozygous concomitant PTCH1 and PTCH2 germline mutations. European Journal of Human Genetics, 2018, 26, 137-142.	1.4	17
184	JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis. Oncotarget, 2015, 6, 37836-37851.	0.8	17
185	Cotreatment with sorafenib and oleanolic acid induces reactive oxygen species-dependent and mitochondrial-mediated apoptotic cell death in hepatocellular carcinoma cells. Anti-Cancer Drugs, 2019, 30, 209-217.	0.7	16
186	<i>NRAS</i>-Mutated Rhabdomyosarcoma Cells Are Vulnerable to Mitochondrial Apoptosis Induced by Coinhibition of MEK and PI3KÎ±. Cancer Research, 2018, 78, 2000-2013.	0.4	15
187	Mouse lung fibroblasts are highly susceptible to necroptosis in a reactive oxygen species-dependent manner. Biochemical Pharmacology, 2018, 153, 242-247.	2.0	15
188	Smac mimetic suppresses tunicamycin-induced apoptosis via resolution of ER stress. Cell Death and Disease, 2019, 10, 155.	2.7	15
189	Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link. Oncotarget, 2011, 2, 418-421.	0.8	15
190	HDAC inhibitors: Double edge sword for TRAIL cancer therapy?. Cancer Biology and Therapy, 2005, 4, 1113-1115.	1.5	14
191	Modulation of apoptosis signaling for cancer therapy. Archivum Immunologiae Et Therapiae Experimentalis, 2006, 54, 173-175.	1.0	14
192	Exploiting apoptosis pathways for the treatment of pediatric cancers. Pediatric Blood and Cancer, 2009, 53, 533-536.	0.8	14
193	Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma. Sarcoma, 2012, 2012, 1-5.	0.7	14
194	SMAC Mimetic BV6 Enables Sensitization of Resistant Tumor Cells but also Affects Cytokine-Induced Killer (CIK) Cells: A Potential Challenge for Combination Therapy. Frontiers in Pediatrics, 2014, 2, 75.	0.9	14
195	Targeting IAP proteins in combination with radiotherapy. Radiation Oncology, 2015, 10, 105.	1.2	14
196	Quantitative singleâ€molecule imaging of TNFR1 reveals zafirlukast as antagonist of TNFR1 clustering and TNFÎ±â€induced NFâ€ÄB signaling. Journal of Leukocyte Biology, 2021, 109, 363-371.	1.5	14
197	Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis. Oncotarget, 2016, 7, 8700-8711.	0.8	14
198	Inhibitor of Apoptosis (IAP) Proteins: Novel Insights into the Cancer-Relevant Targets for Cell Death Induction. ACS Chemical Biology, 2009, 4, 499-501.	1.6	13

#	Article	IF	Citations
199	Targeting Inhibitor of Apoptosis Proteins for Cancer Therapy: A Double-Edge Sword?. Journal of Clinical Oncology, 2014, 32, 3190-3191.	0.8	13
200	Molecular features of the cytotoxicity of an NHE inhibitor: Evidence of mitochondrial alterations, ROS overproduction and DNA damage. BMC Cancer, 2016, 16, 851.	1.1	13
201	Organelle-specific mechanisms of drug-induced autophagy-dependent cell death. Matrix Biology, 2021, 100-101, 54-64.	1.5	13
202	Hypoxia Enhances the Antiglioma Cytotoxicity of B10, a Glycosylated Derivative of Betulinic Acid. PLoS ONE, 2014, 9, e94921.	1.1	13
203	Smac mimetic induces an early wave of gene expression via NF-Î°B and AP-1 and a second wave via TNFR1 signaling. Cancer Letters, 2018, 421, 170-185.	3.2	12
204	A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas. Frontiers in Oncology, 2019, 9, 1271.	1.3	12
205	Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers. Oncotarget, 2016, 7, 49539-49551.	0.8	12
206	Regulation of cell death in cancerâ€"possible implications for immunotherapy. Frontiers in Oncology, 2013, 3, 29.	1.3	11
207	Dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal rhabdomyosarcoma. Cancer Letters, 2015, 360, 1-9.	3.2	11
208	Different Response of Ptch Mutant and Ptch Wildtype Rhabdomyosarcoma Toward SMO and PI3K Inhibitors. Frontiers in Oncology, 2018, 8, 396.	1.3	11
209	The IRE1 and PERK arms of the unfolded protein response promote survival of rhabdomyosarcoma cells. Cancer Letters, 2020, 490, 76-88.	3.2	11
210	Smac mimetic sensitizes renal cell carcinoma cells to interferon-Î±-induced apoptosis. Cancer Letters, 2016, 375, 1-8.	3.2	10
211	Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. Blood, 2000, 95, 301-308.	0.6	10
212	Regulation of Cell Death and Survival by Resveratrol: Implications for Cancer Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 874-879.	0.9	9
213	Manatee invariants reveal functional pathways in signaling networks. BMC Systems Biology, 2017, 11, 72.	3.0	9
214	Thioredoxin inhibitor PX-12 induces mitochondria-mediated apoptosis in acute lymphoblastic leukemia cells. Biological Chemistry, 2020, 401, 273-283.	1.2	9
215	Co-inhibition of BET proteins and PI3KÎ± triggers mitochondrial apoptosis in rhabdomyosarcoma cells. Oncogene, 2020, 39, 3837-3852.	2.6	9
216	ATM inhibition enhances Auranofin-induced oxidative stress and cell death in lung cell lines. PLoS ONE, 2020, 15, e0244060.	1.1	9

#	Article	IF	Citations
217	Identification of Smac mimetics as novel substrates for p-glycoprotein. Cancer Letters, 2019, 440-441, 126-134.	3.2	8
218	Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways. Cell Death and Differentiation, 2020, 27, 1878-1895.	5.0	8
219	Smac mimetics and TRAIL cooperate to induce MLKL-dependent necroptosis in Burkitt's lymphoma cell lines. Neoplasia, 2021, 23, 539-550.	2.3	8
220	Selective BH3-mimetics targeting BCL-2, BCL-X_L or MCL-1 induce severe mitochondrial perturbations. Biological Chemistry, 2019, 400, 181-185.	1.2	8
221	Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines. Oncotarget, 2017, 8, 52445-52456.	0.8	8
222	Targeting Apoptosis Signaling in Pancreatic Cancer. Cancers, 2011, 3, 241-251.	1.7	7
223	Targeting apoptosis pathways in childhood malignancies. Cancer Letters, 2013, 332, 369-373.	3.2	7
224	Inhibitor of Apoptosis Proteins in Pediatric Leukemia: Molecular Pathways and Novel Approaches to Therapy. Frontiers in Oncology, 2014, 4, 3.	1.3	7
225	Reactive oxygen species contribute toward Smac mimetic/temozolomide-induced cell death in glioblastoma cells. Anti-Cancer Drugs, 2016, 27, 953-959.	0.7	7
226	Concomitant targeting of Hedgehog signaling and MCL-1 synergistically induces cell death in Hedgehog-driven cancer cells. Cancer Letters, 2019, 465, 1-11.	3.2	7
227	Differential role of RIP1 in Smac mimetic-mediated chemosensitization of neuroblastoma cells. Oncotarget, 2015, 6, 41522-41534.	0.8	7
228	Novel Promising IAP Antagonist on the Horizon for Clinical Translation. Journal of Medicinal Chemistry, 2012, 55, 4099-4100.	2.9	6
229	Cross Talk Between Cell Death Regulation and Metabolism. Methods in Enzymology, 2014, 542, 81-90.	0.4	6
230	Differential involvement of TAK1, RIPK1 and NF-ÎºB signaling in Smac mimetic-induced cell death in breast cancer cells. Biological Chemistry, 2019, 400, 171-180.	1.2	6
231	STF-62247 and pimozide induce autophagy and autophagic cell death in mouse embryonic fibroblasts. Scientific Reports, 2020, 10, 687.	1.6	6
232	Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large Bâ€cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis. International Journal of Cancer, 2020, 147, 1485-1498.	2.3	6
233	How to target apoptosis signaling pathways for the treatment of pediatric cancers. Frontiers in Oncology, 2013, 3, 22.	1.3	5
234	Hedgehog signaling negatively co-regulates BH3-only protein Noxa and TAp73 in TP53-mutated cells. Cancer Letters, 2018, 429, 19-28.	3.2	5

#	Article	IF	Citations
235	Nextâ€generation sequencing reveals a novel role of lysineâ€specific demethylase 1 in adhesion of rhabdomyosarcoma cells. International Journal of Cancer, 2020, 146, 3435-3449.	2.3	5
236	Apoptosis Signaling Pathways in Anticancer Therapy. Current Cancer Therapy Reviews, 2008, 4, 14-20.	0.2	4
237	NF-ÎºB contributes to Smac mimetic-conferred protection from tunicamycin-induced apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2019, 24, 269-277.	2.2	4
238	Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. International Journal of Cancer, 1998, 76, 105-114.	2.3	4
239	Mitochondria, redox signaling and cell death in cancer. Biological Chemistry, 2016, 397, 583-583.	1.2	4
240	Regulation of the antiapoptotic protein cFLIP by the glucocorticoid Dexamethasone in ALL cells. Oncotarget, 2018, 9, 16521-16532.	0.8	3
241	HIF-1-regulated glucose metabolism in the control of apoptosis signaling. Expert Review of Endocrinology and Metabolism, 2008, 3, 303-308.	1.2	2
242	Editorial: Biology-Driven Targeted Therapy of Pediatric Soft-Tissue and Bone Tumors: Current Opportunities and Future Challenges. Frontiers in Oncology, 2016, 6, 39.	1.3	2
243	Apoptotic Cells induce Proliferation of Peritoneal Macrophages. International Journal of Molecular Sciences, 2021, 22, 2230.	1.8	2
244	IFNÎ³ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. , 0, .		2
245	Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. , 0, .		2
246	Small Molecule XIAP Inhibitors Cooperate with TRAIL to Trigger Apoptosis in Childhood Acute Leukemia Cells and Overcome Bcl-2-Mediated Resistance. Blood, 2008, 112, 857-857.	0.6	2
247	Regulation of cancer stem-like cell differentiation by Smac mimetics. Molecular and Cellular Oncology, 2014, 1, e960769.	0.3	1
248	Strategies to Overcome TRAIL Resistance in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 157-166.	0.1	0
249	Harnessing Death Receptor Signaling for Cancer Treatment. , 2013, , 281-301.		0
250	Editorial. Cancer Letters, 2013, 332, 132.	3.2	0
251	Redox regulation of Smac mimetic-induced cell death. Molecular and Cellular Oncology, 2015, 2, e1000697.	0.3	0
252	Apoptosis Induced by Extracts of Helleborus Niger in Different Lymphoma and Leukemia Cell Lines and Primary Lymphoblasts of Children with ALL Is Independent of Smac-Overexpression and Executed Via the Mitochondrial Pathway.. Blood, 2007, 110, 4215-4215.	0.6	0

#	Article	IF	Citations
253	A Novel Paradigm to Trigger Apoptosis in Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 731-731.	0.6	0
254	Deregulated Apoptotic Pathways Point to Effectiveness of IAP Inhibitor Therapy in Acute Myeloid Leukemia.. Blood, 2009, 114, 1275-1275.	0.6	0
255	XIAP Inhibitors Present a Promising New Strategy to Sensitize Childhood Acute Leukemia Cells for Chemotherapy-Induced Apoptosis.. Blood, 2009, 114, 3791-3791.	0.6	0
256	IAPs and Resistance to Death Receptors in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 59-77.	0.1	0
257	Hereditary Ovarian and Endometrial Cancer. , 0, , 207-214.		0
258	Wilms and Rhabdoid Tumors of the Kidney. , 0, , 231-243.		0
259	Hereditary Renal Tumors of the Adult. , 0, , 245-256.		0
260	Gastrointestinal Polyposis Syndromes. , 0, , 257-280.		0
261	Hereditary Gastric Cancer. , 0, , 309-343.		0
262	Genetic Counseling for Hereditary Tumors. , 0, , 467-485.		0
263	Hereditary Cancer in the Head and Neck. , 0, , 163-168.		0